Chr. Hansen Holding A/S Interim Report Q1 2022/23
January 12, 2023 – Company announcement no. 1
Solid Q1 supports the outlook for 2022/23
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our underlying target for the year but update the outlook to reflect current exchange rate levels.
We will maintain a clear and strong focus on executing on our targets for the financial year 2022/23 while preparing for the proposed merger with Novozymes, which offers an exciting opportunity to create a leading global biosolutions partner based on strong complementary technology platforms, highly dedicated employees and a customer-centric approach.”
Q1 2022/23 highlights
- Revenue amounted to EUR 310 million, up 15% from EUR 268 million in Q1 2021/22.
- Organic growth was 10% in Q1 2022/23 driven by a mix of volume and price growth. Food Cultures & Enzymes organic growth was 8% mainly driven by price initiatives, but with good volume growth above underlying markets. Health & Nutrition organic growth was 12% driven by volume. The Lighthouses (Bioprotection, Fermented Plant Bases, Plant Health and HMO) was impacted by timing of orders and delivered 4% organic growth combined in Q1, while the core businesses delivered 10% organic growth.
- EBIT b.s.i. amounted to EUR 77 million, up 17% from EUR 65 million in Q1 2021/22. The increase was driven by a positive contribution from exchange rates and pricing initiatives, which was partly offset by a negative impact from higher input costs.
- The EBIT margin b.s.i. was 24.7%, up from 24.4% in Q1 2021/22. The improved margin was due to a positive contribution from exchange rates, which was partly offset by continuing inflationary pressures, despite ongoing price initatives.
- Free cash flow b.a.s.i. amounted to EUR 17 million, down from EUR 55 million last year, as the cash flow from operating activities b.a.s.i. was negatively impacted by a change in working capital and higher taxes paid.
- On December 12, 2022 Chr. Hansen and Novozymes announced that the two companies had entered into an agreement to create a leading global biosolutions partner through a statutory merger. Work has been initiated to seek customary merger control and other regulatory approvals from relevant authorities, while the extraordinary general meeting for shareholder approval is currently expected to be held in the first half of the calendar year 2023.
The current exchange rate level for the EUR/USD stands at 1.07 versus 0.97 at the time of the initial 2022/23 outlook provided on October 12, 2022. To reflect the 10% depreciation of the USD we update the outlook for the year regarding the impact from exchange rates on revenue, EBIT margin b.s.i. and cashflow b.a.s.i. The expectations to the underlying business incl. organic growth, EBIT margin b.s.i. and cash flow b.a.s.i. net of exchange rates remain unchanged.
- Organic revenue growth is expected in the range of 7-10% (unchanged)
- Impact from exchange rates on revenue will be neutral (previously positive 5%)
- EBIT b.s.i. is expected to grow in line with revenue (previously faster than revenue)
- EBIT margin b.s.i. is expected to be 26-27% (previously 27-28%)
- Free cash flow b.a.s.i. is expected to be around EURm 170-210 (previously EURm 190-230)
The outlook for 2022/23 is based on actual exchange rates until January 11, 2023, and for the remainder of the year assuming constant exchange rates at the current level of EUR/USD rate of 1.07. For further details on the outlook for 2022/23, please refer to page 10.
See attachment for full Q1 2022/23 interim report.
Anders Mohr Christensen, VP Group Strategy & Investor Relations, +45 25 15 23 64
Cristina Rønde Hefting, Senior Investor Relations Manager, +45 40 72 12 24
About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Orkuveita Reykjavíkur | Green Bond Auction December 125.12.2023 18:17:17 CET | Press release
Reykjavík Energy (Orkuveita Reykjavíkur; OR) is holding a bond auction on Tuesday, December 12th, 2023. Bonds in the green bond classes OR020934 GB, OR180255 GB and OR161126 GB will be offered for sale. OR161126 GB bears non-indexed interests with an interest payment arrangement and bears 7.0% interest, payable four times a year until the final maturity on November 16, 2026. Previously, bonds with a nominal value of 720 million have been issued in the class. OR020934 GB bears fixed indexed interests and pays equal payments every six months with a final maturity date of September 2, 2034. Previously, bonds with a nominal value of ISK 21,127 million have been issued in the class. OR0180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18, 2055. Previously, bonds with a nominal value of ISK 27,281 million have been issued in the class. Fossar Investment Bank hf. oversees the issuance and sale of the bonds as well as their a
Wereldhave acquires shopping center Polderplein in Hoofddorp, the Netherlands, and enters growth phase of its LifeCentral strategy5.12.2023 17:40:00 CET | Press release
Wereldhave has reached agreement with DELA Vastgoed B.V. (‘DELA’) regarding the acquisition of shopping center Polderplein and its parking garage in Hoofddorp (The Netherlands), with a total gross lettable area of c17,000 m² (excluding parking). The acquisition perfectly fits within Wereldhave’s strategy and acquisition criteria such as location, value creation opportunities and synergies with the recently delivered Full Service Center Vier Meren. Combined, Vier Meren and Polderplein will create one dominant Full Service Center in the best location of the city, with 49,100 m2 lettable area and 105 shops, with Wereldhave as sole owner. The total purchase price amounts to € 74m (€ 82m including transaction costs), reflecting a net initial yield of 7.6%. As the transaction is 70% equity financed, the loan-to-value will improve by c30bps. Matthijs Storm, CEO of Wereldhave commented: “This acquisition marks the start of the growth phase of Wereldhave’s LifeCentral strategy and completes a b
Kvika banki hf.: Result of subordinated bond offering5.12.2023 17:39:25 CET | Press release
Kvika has today concluded an offering of Tier-2 subordinated bonds in a new series, KVIKA 34 1211 T2i. Total demand amounted to ISK 4,820 million. The subordinated bonds were sold at par for an amount of ISK 2,000 million, where total issuance in the series is limited to ISK 4,000 million. The subordinated bonds are index linked and have an annual coupon of 6.25%. The maturity of the bonds is 11 December 2034 and are callable by the issuer at the interest payment date of 11 December 2029 and on every subsequent interest payment date. The subordinated bonds will be issued under Kvika’s EMTN programme and listed on Nasdaq Iceland. For further information please contact Kvika‘s investor relations at firstname.lastname@example.org
Zoom named a Leader in the 2023 Gartner® Magic Quadrant™ for UCaaS, Worldwide5.12.2023 17:31:56 CET | Press release
Zoom Celebrates its Fourth Consecutive Time in the Leaders Quadrant SAN JOSE, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), today announced that analyst firm Gartner has named Zoom a Leader in the 2023 Gartner® Magic Quadrant™ for Unified Communications as a Service (UCaaS), Worldwide for the fourth time in a row. The UCaaS report evaluated 11 companies in the unified communications space, and Zoom has been recognized as a Leader in this space for its UCaaS offerings. Zoom includes enterprise-grade solutions like Zoom Team Chat, Zoom Phone, Zoom Meetings, Zoom Contact Center, and Zoom AI Companion. “We are excited to be named a Leader in the Gartner Magic Quadrant for UCaaS for the fourth consecutive year which we feel is a result of our ongoing commitment to offer an exceptional UCaaS experience," said Graeme Geddes, Chief Growth Officer at Zoom. “As we continue to innovate and evolve our platform, we remain true to solving real customer probl
Innofactor Plc: Share Repurchase 5.12.20235.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 5.12.2023Innofactor Plc: Share Repurchase 5.12.2023In the Helsinki Stock ExchangeTrade date 5.12.2023Bourse trade BuyShare IFA1VAmount 4,600SharesAverage price/ share 1.1465EURTotal cost 5,273.90EURInnofactor Plc now holds a total of 571 129 sharesincluding the shares repurchased on 5.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 email@example.com Attachment Innofactor_5.12_trades